1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drugs In Development, 2022, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 18, 147, 186, 9, 18, 307, 80 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 21, 30, 9, 1, 58 and 29 molecules, respectively.
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects, 2022
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products, 2022
- Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2Seventy Bio Inc
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AB Science SA
- AbbVie Inc
- AbTis Co Ltd
- Accro Bioscience Suzhou Co Ltd
- Acrotech Biopharma LLC
- Actinium Pharmaceuticals Inc
- Actinobac Biomed Inc
- ADC Therapeutics SA
- ADCendo ApS
- Adlai Nortye Biopharma Co Ltd
- Advanced BioDesign
- Advenchen Laboratories LLC
- Affichem SA
- Affimed GmbH
- Agastiya Biotech LLC
- Agenus Inc
- AIkido Pharma Inc
- Aileron Therapeutics Inc
- AIMM Therapeutics BV (Inactive)
- Akeso Inc
- Alaunos Therapeutics Inc
- Allogene Therapeutics Inc
- ALX Oncology Holdings Inc
- Ambrx Biopharma Inc
- Amgen Inc
- Amogen Pharma Pvt Ltd
- Amphivena Therapeutics Inc
- Amplia Therapeutics Ltd
- Angiocrine Bioscience Inc
- ANP Technologies Inc
- Antengene Corp Ltd
- Antisense Therapeutics Ltd
- AnyGen Co Ltd
- APIM Therapeutics AS
- Aprea Therapeutics Inc
- AptaBio Therapeutics Inc
- Aptevo Therapeutics Inc
- Aptose Biosciences Inc
- Aravive Inc
- Arcellx Inc
- Argenx SE
- Armaceutica Inc
- Arog Pharmaceuticals Inc
- Arrien Pharmaceuticals LLC
- Ascentage Pharma Group International
- Aslan Pharmaceuticals Ltd
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Athos Therapeutics Inc
- ATP Biopharm
- Aucentra Therapeutics Pty Ltd
- AUM Biosciences Pte Ltd
- Auransa Inc
- Aurigene Discovery Technologies Ltd
- Autolus Therapeutics Plc
- AvenCell Europe GmbH
- AVROBIO Inc
- Avvinity Therapeutics Ltd
- Axter Therapeutics Ltd
- BAKX Therapeutics Inc
- Bantam Pharmaceutical LLC
- Base Therapeutics
- Bayer AG
- BCI Pharma SA
- Beactica Therapeutics AB
- Beam Therapeutics Inc
- BeiGene Ltd
- Beijing Immunochina Pharmaceuticals Co Ltd
- Beijing JD Biotech Co Ltd
- Beijing Konruns Pharmaceutical Co Ltd
- Beijing Mabworks Biotech Co Ltd
- Beijing StarMab BioMed Technology Ltd
- Bellicum Pharmaceuticals Inc
- BerGenBio ASA
- Beroni Group Ltd
- Betta Pharmaceuticals Co Ltd
- Bio-Cancer Treatment International Ltd
- Bio-Path Holdings Inc
- Biokine Therapeutics Ltd
- BioLineRx Ltd
- Biomea Fusion Inc
- BioMed Valley Discoveries Inc
- BiOneCure Therapeutics Inc
- Bionomics Ltd
- BioSight Ltd
- Biosplice Therapeutics Inc
- BioTheryX Inc
- BioXcel Therapeutics Inc
- Bivictrix Therapeutics PLC
- Blueprint Medicines Corp
- BlueSphere Bio Inc
- Boehringer Ingelheim International GmbH
- Boryung ViGenCell Inc
- BoYen Therapeutics Inc
- Bridge Medicines LLC
- BridGene Biosciences Inc
- Bristol-Myers Squibb Co
- C4 Therapeutics Inc
- Calithera Biosciences Inc
- Canqura Oncology AB
- Canthera Discovery
- Captor Therapeutics SA
- Carbiogene Therapeutics Co Ltd
- Cardiff Oncology Inc
- Caribou Biosciences Inc
- Carrick Therapeutics Ltd
- Catalent Inc
- CellCentric Ltd
- Cellectis SA
- Cellerant Therapeutics Inc
- Celularity Inc
- Celyad Oncology SA
- Center for Genetic Engineering and Biotechnology
- Centrose LLC
- Centrymed Pharmaceutical Inc
- Changzhou Qianhong Bio-Pharma Co Ltd
- CharlestonPharma LLC
- Checkpoint Therapeutics Inc
- Cheetah Cell Therapeutics Co Ltd
- Chemestmed OU
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chimeric Therapeutics Ltd
- Chimerix Inc
- China Immunotech (Beijing) Biotechnology Co Ltd
- Chongqing Precision Biotech Co Ltd
- Chongqing Zhixiang Jintai Bio-Pharmaceutical Co Ltd
- Chordia Therapeutics Inc
- Chugai Pharmaceutical Co Ltd
- CicloMed LLC
- Cleave Therapeutics Inc
- Cogent Biosciences Inc
- CoImmune Inc
- Cornerstone Pharmaceuticals Inc
- CRISPR Therapeutics AG
- CrystalGenomics Inc
- CSPC Pharmaceutical Group Ltd
- CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
- CTCELLS Inc
- Cue Biopharma Inc
- Cullinan Oncology Inc
- Curacle Co Ltd
- CuronBiotech Inc
- Cyclacel Pharmaceuticals Inc
- CytoImmune Therapeutics Inc
- Daiichi Sankyo Co Ltd
- Dalriada Therapeutics Inc
- Delta-Fly Pharma Inc
- Demuris Ltd
- Denovo Biopharma LLC
- Deverra Therapeutics Inc
- Diaccurate
- Diatheva srl
- Dimericon Therapeutics AG
- DiNonA Inc
- Dong Wha Pharma Co Ltd
- Duet Therapeutics Inc
- Dynamic Cell Therapies Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Ellipses Pharma Ltd
- Elpis Biopharmaceuticals Corp
- Elucida Oncology Inc
- Emercell SAS
- Eminent Biosciences
- EntreChem SL
- Enzyme by Design Inc
- Epigene Therapeutics Inc
- Epizyme Inc
- Escend Pharmaceuticals Inc
- Etern BioPharma Co Ltd
- Eterna Therapeutics Inc
- ExCellThera Inc
- Exonate Ltd
- Expression Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Faron Pharmaceuticals Oy
- Fate Therapeutics Inc
- FatiAbGen Corp
- FibroGen Inc
- Fimecs Inc
- Flavocure Biotech LLC
- Fujifilm Holdings Corp
- FutureGen Biopharm Technology Co Ltd
- Gadeta BV
- GammaDelta Therapeutics Ltd
- Genentech USA Inc
- GeneScience Pharmaceuticals Co Ltd
- GenFleet Therapeutics (Shanghai) Inc
- Genmab AS
- Genosco Inc
- Genus Oncology LLC
- Geron Corp
- Gilead Sciences Inc
- GlycoMimetics Inc
- Glycostem Therapeutics BV
- Golden Biotechnology Corp
- GPCR Therapeutics Inc
- Gracell Biotechnologies Inc
- Greenfire Bio LLC
- GSK plc
- GT Biopharma Inc
- Guangzhou Bio-gene Technology Co Ltd
- Hangzhou Bensheng Pharmaceutical Co Ltd
- Hangzhou DAC Biotech Co Ltd
- Hangzhou Puji Yuancheng Biomedical Technology Co Ltd
- Hangzhou Qihan Biotechnology Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Hebei Senlang Biotechnology Co Ltd
- HEC Pharma Co Ltd
- Hefei Cosource Pharmaceutical Inc
- Helocyte Biosciences Inc
- HemoGenyx Pharmaceuticals Plc
- HighPass Bio Inc
- Hillstream BioPharma Inc
- Hinova Pharmaceuticals Co Ltd
- HK inno.N Corp
- Horizon Therapeutics Plc
- Hoth Therapeutics Inc
- Hoverink Biotechnologies Inc
- Hunan Siweikang Therapeutics Ltd
- Hutchison MediPharma Ltd
- HUYA Bioscience International LLC
- Hybrigenics SA
- I-Mab
- iCell Gene Therapeutics LLC
- IGM Biosciences Inc
- Imago BioSciences Inc
- Imbioray (Hangzhou) Biomedicine Co Ltd
- ImCheck Therapeutics SAS
- Immune Onc Therapeutics Inc
- Immune System Key Ltd
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- ImmunityBio Inc
- ImmunoAct Pvt Ltd
- Immunocore Holdings Plc
- ImmunoGen Inc
- IN8bio Inc
- Inatherys
- Incyte Corp
- Inflection Biosciences Ltd
- Inmune Bio Inc
- Innate Pharma SA
- InnoCare Pharma Ltd
- InnoPharmaScreen Inc
- Innovation Pharmaceuticals Inc
- Innovent Biologics Inc
- InSilico Medicine
- Interprotein Corp
- Intra-Immusg Pvt Ltd
- Invivoscribe Inc
- Io Therapeutics Inc
- Ipsen SA
- Isoprene Pharmaceuticals Inc
- Iterion Therapeutics Inc
- Jacobio Pharmaceuticals Group Co Ltd
- January Therapeutics Inc
- Jasper Therapeutics Inc
- Jazz Pharmaceuticals Plc
- Jeil Pharmaceutical Co Ltd
- Jiangsu Aidea Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Lianhuan Pharmaceutical Co Ltd
- Jiangxi Shanxing Biotechnology Co Ltd
- Johnson & Johnson
- JSK Therapeutics Inc
- Jubilant Therapeutics Inc
- Juventas Cell Therapy Ltd
- JW Pharmaceutical Corp
- KAHR medical Ltd
- Kainos Medicine Inc
- Kartos Therapeutics Inc
- Karyopharm Therapeutics Inc
- KeViRX Inc
- Kiadis Pharma NV
- KinaRx LLC
- Kintor Pharmaceutical Ltd
- KisoJi Biotechnology Inc
- Kronos Bio Inc
- Kura Oncology Inc
- Kurome Therapeutics Inc
- Kymera Therapeutics Inc
- Kyorin Pharmaceutical Co Ltd
- Lai Corporation Pty Ltd
- LAVA Therapeutics NV
- Lead Discovery Center GmbH
- Legend Biotech Corp
- LegoChem Biosciences Inc
- Les Laboratoires Servier SAS
- Leukos Biotech SL
- Lotus Pharmaceutical Co Ltd
- LTZ Therapeutics Inc
- Lynk Pharmaceutical Hangzhou Co Ltd
- Mablink Bioscience
- Mabwell Shanghai Bioscience Co Ltd
- Machavert Pharmaceuticals LLC
- MacroGenics Inc
- Mana Therapeutics Inc
- Marker Therapeutics Inc
- Maxinovel Pharmaceuticals
- MedAbome Inc
- MediGene AG
- MediSix Therapeutics Pte Ltd
- MedPacto Inc
- MEI Pharma Inc
- Mendus AB
- Merck & Co Inc
- Merck KGaA
- Meryx Inc
- Millennium Pharmaceuticals Inc
- Miltenyi Biomedicine GmbH
- Minneamrita Therapeutics LLC
- MiRx Pharmaceuticals LLC
- Mito BioPharm LLC
- Molecular Partners AG
- Molecular Templates Inc
- Molecules For Health Inc
- Moleculin Biotech Inc
- Morphiex Biotherapeutics Inc
- MorphoSys AG
- Multitude therapeutics Inc
- Mustang Bio Inc
- MyeloRx LLC
- Nanchang Hongyi Pharmaceutical Co Ltd
- Nanjing IASO Biotherapeutics Co Ltd
- Nanjing Ruijie Pharmaceutical Technology Co Ltd
- Nanjing Sanhome Pharmaceutical Co Ltd
- Nanoligent SL
- NanoPharmaceuticals LLC
- NanoValent Pharmaceuticals Inc
- Nemucore Medical Innovations Inc
- Nerviano Medical Sciences SRL
- New Beta Innovation Ltd
- Newave Pharmaceutical Inc
- NextCure Inc
- NGM Biopharmaceuticals Inc
- Nkarta Inc
- Nohla Therapeutics Inc
- Northlake International LLC
- Novartis AG
- Novelty Nobility Inc
- Novorex Inc
- Nuvation Bio Inc
- Oita University Institute of Advanced Medicine Inc
- Omeros Corp
- OncoC4 Inc
- Oncoheroes Biosciences Inc
- Oncolytics Biotech Inc
- Oncolyze Inc
- OncoMyx Therapeutics Inc
- Oncopeptides AB
- OncoTartis Inc
- Oncotelic Therapeutics Inc
- One-Carbon Therapeutics AB
- ONK Therapeutics Ltd
- Ono Pharmaceutical Co Ltd
- Opna Bio SA
- Opsyon
- Orano Med LLC
- Orca Biosystems Inc
- Orum Therapeutics Inc
- Oryzon Genomics SA
- Ossium Health Inc
- Otsuka Pharmaceutical Co Ltd
- Oxcia AB
- Oxford BioMedica Plc
- Pacylex Pharmaceuticals Inc
- Paean Biotechnology Inc
- PCG-Biotech Co Ltd
- PDS Biotechnology Corp
- PeLeMed Co Ltd
- PendreaBio Inc
- Penrose Therapeutix LLC
- PentixaPharm GmbH
- PersonGen BioTherapeutics (Suzhou) Co Ltd
- Pfizer Inc
- Pharma Mar SA
- PharmCADD Co Ltd
- Pharos iBio Co Ltd
- Phebra Pty Ltd
- Phi Pharma SA
- Phoenix Molecular Designs
- PhoreMost Ltd
- Picobella LLC
- Pimera Inc
- PiNK Biopharma Ltd
- Pinotbio Inc
- Pinteon Therapeutics Inc
- Pleco Therapeutics BV
- Plexium Inc
- Plexxikon Inc
- Polaris Pharmaceuticals Inc
- Prelude Therapeutics Inc
- Prescient Therapeutics Ltd
- Primetime Life Sciences LLC
- PRISM Pharma Co Ltd
- Promutech Pharmaceuticals Inc
- Proteintech Group Inc
- Protheragen Inc
- Provectus Biopharmaceuticals Inc
- Provention Bio Inc
- PTC Therapeutics Inc
- Puretech Health Plc
- PYC Therapeutics Ltd
- Qilu Pharmaceutical Co Ltd
- QLSF Biotherapeutics Inc
- Qualigen Therapeutics Inc
- Qurient Co Ltd
- Race Oncology Ltd
- Rain Therapeutics Inc
- Rasio Therapeutics Inc
- Rasna Therapeutics Inc
- Regenacy Pharmaceuticals LLC
- ReguGene Co Ltd
- Relevant Biosciences Inc
- Remedy Plan Inc
- Rigel Pharmaceuticals Inc
- Roivant Sciences Ltd
- Ryvu Therapeutics SA
- SA Science Inc
- Salarius Pharmaceuticals Inc
- Samus Therapeutics Inc
- Sandhill Therapeutics Inc
- Sanofi
- Sapience Therapeutics Inc
- Sardona Therapeutics Inc
- Sareum Holdings Plc
- Schrodinger Inc
- Seagen Inc
- SELLAS Life Sciences Group Inc
- Senhwa Biosciences Inc
- Senti Biosciences Inc
- SFA Therapeutics Inc
- Shanghai icell Biotechnology Co Ltd
- Shanghai Pharmaceuticals Holding Co Ltd
- Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
- Shanghai YaKe Biotechnology Co Ltd
- Shanghai Zeke Biotech Co Ltd
- Shattuck Labs Inc
- Shengke Pharmaceuticals (Jiangsu) Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- Shorla Pharma Ltd
- Shouyao Holding Co Ltd
- Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
- SideROS
- SignalChem Lifesciences Corp
- Sinco Pharmaceuticals Holdings Ltd
- Sino Biopharmaceutical Ltd
- SiNOPSEE Therapeutics Pte Ltd
- Sisu Pharma Inc
- Smart Immune SAS
- Sorrento Therapeutics Inc
- SphingoGene Inc
- Stelexis Therapeutics LLC
- Stemirna Therapeutics Ltd
- StingInn LLC
- Storm Therapeutics Ltd
- Sumitomo Dainippon Pharma Oncology, Inc
- Sumitomo Pharma Co Ltd
- Sutro Biopharma Inc
- SuviCa Inc
- Suzhou JiSheng Pharmaceutical Co Ltd
- Suzhou Maximum Bio-tech Co Ltd
- Synactix Pharmaceuticals Inc
- Syndax Pharmaceuticals Inc
- SYNIMMUNE GmbH
- Syros Pharmaceuticals Inc
- Systimmune Inc
- T-CURX GmbH
- Tacitus Therapeutics Inc
- Taivex Therapeutics Inc
- Takara Bio Inc
- Takeda Pharmaceutical Co Ltd
- Talem Therapeutics Inc
- TC BioPharm Ltd
- TCR2 Therapeutics Inc
- TeamedOn International Inc
- Telios Pharma Inc
- Telix Pharmaceuticals Ltd
- Tetranov International Inc
- Teva Pharmaceutical Industries Ltd
- Tiziana Life Sciences Plc
- Toko Pharmaceutical Industries Co Ltd
- TOLREMO Therapeutics AG
- TOT Biopharm Co Ltd
- TransThera Sciences (Nanjing) Inc
- Treadwell Therapeutics Inc
- Triphase Accelerator Corp
- TScan Therapeutics Inc
- TSD Life Sciences
- Tubulis GmbH
- UbiVac Inc
- UTC Therapeutics Inc
- Varian Biopharmaceuticals Inc
- Vertex Pharmaceuticals Inc
- Veru Inc
- Vessel Scientific LLC
- Vichem Chemie Research Ltd
- Vincerx Pharma Inc
- VioQuest Pharmaceuticals Inc (Inactive)
- Viracta Therapeutics Inc
- Viridian Therapeutics Inc
- VM Discovery Inc
- Vor BioPharma Inc
- Vyriad Inc
- Wellington Zhaotai Therapies Ltd
- Wigen Biomedicine Technology (Shanghai) Co Ltd
- Wugen Inc
- Wuhan Bio-Raid Biotechnology Co Ltd
- Wyze Biotech Co Ltd
- XEME BioPharma Inc
- Xencor Inc
- XNK Therapeutics AB
- Y-mAbs Therapeutics Inc
- Yeda Research and Development Company Ltd
- Yungjin Pharm Co Ltd
- Zenith Epigenetics Ltd
- Zentalis Pharmaceuticals Inc
- Zhengda Tianqing Pharmaceutical Group Co Ltd
- Zovis Pharmaceuticals
